» Authors » Britta Siegmund

Britta Siegmund

Explore the profile of Britta Siegmund including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 278
Citations 7157
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kinzel T, Reich V, Schuhmacher L, Bojarski C, Adler A, Veltzke-Schlieker W, et al.
Endosc Int Open . 2025 Feb; 13:a25112096. PMID: 40018077
Background And Study Aims: The direct puncture technique has been associated with a better safety profile compared with the classical pull-through technique for insertion of a percutaneous endoscopic gastrostomy (PEG)....
2.
Martinez-Medina J, Ghazisaeedi F, Kramer C, Ziegler J, McParland V, Monch P, et al.
Gut Microbes . 2025 Feb; 17(1):2464296. PMID: 39980334
Understanding the dynamic relationship between mucus-associated microbiota and host health is critical. However, studies predominantly using stool samples may not accurately represent these bacterial communities. Here, we investigated the mucus-associated...
3.
Panaccione R, Ferrante M, Dotan I, Panes J, Hisamatsu T, Bossuyt P, et al.
Clin Gastroenterol Hepatol . 2025 Feb; PMID: 39909280
Background & Aims: The efficacy and safety of extended treatment with risankizumab (RZB), an anti-interleukin-23 p19 monoclonal antibody, were evaluated in patients with moderate to severe Crohn's disease (CD) who...
4.
Budzinski L, Kang G, Riedel R, Sempert T, Lietz L, Maier R, et al.
Gut Microbes . 2025 Jan; 17(1):2452250. PMID: 39815413
IgA-coated fractions of the intestinal microbiota of Crohn's disease (CD) patients have been shown to contain taxa that hallmark the compositional dysbiosis in CD microbiomes. However, the correlation between other...
5.
Bao L, Yu Y, Gonzalez-Acera M, Patankar J, Giessl A, Sturm G, et al.
Sci Transl Med . 2025 Jan; 17(781):eadn8699. PMID: 39813315
Dysregulation at the intestinal epithelial barrier is a driver of inflammatory bowel disease (IBD). However, the molecular mechanisms of barrier failure are not well understood. Here, we demonstrate dysregulated mitochondrial...
6.
Avery E, Haag L, McParland V, Kedziora S, Zigra G, Valdes D, et al.
Cardiovasc Res . 2025 Jan; PMID: 39804196
Aims: The gastrointestinal (GI) tract is composed of distinct sub-regions, which exhibit segment-specific differences in microbial colonization and (patho)physiological characteristics. Gut microbes can be collectively considered as an active endocrine...
7.
Ferrante M, DHaens G, Jairath V, Danese S, Chen M, Ghosh S, et al.
Lancet . 2024 Nov; 404(10470):2423-2436. PMID: 39581202
Background: Mirikizumab, a humanised monoclonal antibody that inhibits IL-23p19, is effective in moderate-to-severe ulcerative colitis. We aimed to evaluate the efficacy and safety of mirikizumab in patients with moderately-to-severely active...
8.
Liu W, Mao R, Nga Le T, West G, Varadharajan V, Banerjee R, et al.
Gastroenterology . 2024 Nov; 168(3):508-524. PMID: 39522890
Background & Aims: In Crohn's disease, wrapping of mesenteric fat around the bowel wall, so-called "creeping fat," is highly associated with strictures. The strongest contributor to luminal narrowing in strictures...
9.
10.
Atreya R, Ferrante M, Panaccione R, Feagan B, Shchukina O, Jairath V, et al.
J Crohns Colitis . 2024 Nov; PMID: 39485390
Background And Aims: Normalization of high-sensitivity C-reactive protein [hs-CRP] and fecal calprotectin [FCP] are suggested Crohn's disease [CD] intermediate treatment targets. This analysis evaluates achievement of biomarker normalization and the...